Skip to main content

Peer Review reports

From: A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

Original Submission
27 Apr 2021 Submitted Original manuscript
19 May 2021 Reviewed Reviewer Report - Takafumi Koyama
23 May 2021 Reviewed Reviewer Report
19 Jun 2021 Author responded Author comments - Stephen Booth
Resubmission - Version 2
19 Jun 2021 Submitted Manuscript version 2
28 Jun 2021 Author responded Author comments - Stephen Booth
Resubmission - Version 3
28 Jun 2021 Submitted Manuscript version 3
Publishing
6 Jul 2021 Editorially accepted
23 Jul 2021 Article published 10.1186/s12885-021-08595-w

You can find further information about peer review here.

Back to article page